This study aimed to compare the inhibitory effect of flunixin meglumine and meloxicam on the smooth muscles of the gastrointestinal tract in male cattle. Tissue samples, including the abomasum, ileum, proximal loop and centripetal gyri of the ascending colon, were collected from routinely slaughtered male cattle. These samples were sectioned into strips and mounted in an isolated tissue bath system.
View Article and Find Full Text PDFHighly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials.
View Article and Find Full Text PDFBackground/aim: Syndesmophyte formation appears to be site-specific in ankylosing spondylitis (AS) and new bone formation seems to occur in regions of microtrauma that are prone to tensile forces. Pelvic and spinal parameters are unique for each individual. Pelvic tilt and sacral slope are important anatomical features that compensate in harmony in keeping the sagittal balance.
View Article and Find Full Text PDFWolfram syndrome (WS) is a rare condition caused by homozygous or compound heterozygous mutations in the WFS1 gene primarily. It is diagnosed on the basis of early-onset diabetes mellitus and optic nerve atrophy. Patients complain of trigeminal-like migraines and show deficits in vibration sensation, but the underlying cause is unknown.
View Article and Find Full Text PDFObjective: Cyclin D1 (CDDN1) is an important protein for mitotic cell cycle advancement through the G1 phase and contributes to the control of the cyclin-dependent kinases CDK4 and CDK6. We evaluated the relationship between CDDN1 expression and clinicopathological features in prostate cancer (PCa) cases and whether CDDN1 could be used as a prognostic biomarker for PCa cases in this study.
Methods: This study comprised ninety cases; seventy-five had PCa and fifteen had benign prostatic hypertrophy (BPH) diagnoses (as the control group).